NCT04424966 2025-10-24
Infigratinib in Recurrent High-Grade Glioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Terminated
Clinical Trials
7 trialsNCT04228042 2025-01-01
Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT06206278 2024-08-14
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
LianBio LLC
Phase 2 Terminated
NCT03773302 2024-05-08
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT04197986 2024-03-13
PROOF302
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT02160041 2019-06-18
CBGJ398XUS04
Novartis
Phase 2 Terminated
NCT02706691 2019-04-16
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
University of Chicago
Phase 2 Terminated